Inhibition of gastric inhibitory polypeptide signaling prevents obesity
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Secretion of gastric inhibitory polypeptide (GIP), a duodenal hormone, is primarily induced by absorption of ingested fat. Here we describe a novel pathway of obesity promotion via GIP. Wild-type mice fed a high-fat diet exhibited both hypersecretion of GIP and extreme visceral and subcutaneous fat deposition with insulin resistance. In contrast, mice lacking the GIP receptor (Gipr(-/-)) fed a high-fat diet were clearly protected from both the obesity and the insulin resistance. Moreover, double-homozygous mice (Gipr(-/-), Lep(ob)/Lep(ob)) generated by crossbreeding Gipr(-/-) and obese ob/ob (Lep(ob)/Lep(ob)) mice gained less weight and had lower adiposity than Lep(ob)/Lep(ob) mice. The Gipr(-/-) mice had a lower respiratory quotient and used fat as the preferred energy substrate, and were thus resistant to obesity. Therefore, GIP directly links overnutrition to obesity and it is a potential target for anti-obesity drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“tirzepatide proved superior in improving glycemic control relative to treatment with semaglutide (1 mg)133, insulin degludec134, insulin glargine135,136, and insulin lispro137; importantly, with preserved efficacy and without compromising safety in subjects at risk for cardiovascular diseases136.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“Despite the slight differences based on the subject cohort and the duration of treatment, this magnitude of weight loss was largely consistent with the SURPASS trials132-140.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“Combined, the SURPASS and SURMOUNT trials have verified the safety of tirzepatide to be consistent with GLP-1R agonists, along with its enhanced efficacy at maximal doses of 5, 10 and 15 mg (Table 1)132-136,143,145-147”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“While GIPR antagonism has been shown to reduce adiposity in preclinical models [64], the clinical data show tirzepatide, a dual GLP-1R/GIPR agonist, produces greater weight loss and glucose lowering than the GLP-1R agonist semaglutide alone [42], particularly at doses which comparably engage the GLP-1R [61].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [64]
In the citing paper
“Initial reports that GIPR null mice [64] are protected from diet-induced obesity have been supported by preclinical studies in rodents and non-human primates that GIPR antagonism induces additive weight loss when combined with GLP-1R agonism [32,67], and human genetics data that loss-of-function GIPR variants associate with reduced adiposity [68].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [64]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419 · cited 1×
“Obese Lep ob / Lep ob mice exhibit a marked increase in adipose tissue due to hyperphagia caused by mutation of the leptin gen”
BackgroundSerum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans
Considine, R. V., Sinha, M. K., Heiman, M. L., Kriauciunas, A., Stephens, T. W., Nyce, M. R., Ohannesian, J. P., Marco, C. C., McKee, L. J., Bauer, T. L., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340503 · Cited by 6,326
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
Weight-Reducing Effects of the Plasma Protein Encoded by the obese Gene
Halaas, J. L., Gajiwala, K. S., Maffei, M., Cohen, S. L., Chait, B. T., Rabinowitz, D., Lallone, R. L., Burley, S. K., & Friedman, J. M. (1995) · Science · doi:10.1126/science.7624777 · Cited by 4,451
Obesity and insulin resistance
Kahn, B. B., & Flier, J. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10842 · Cited by 3,225
Obesity and the regulation of energy balance
Spiegelman, B. M., & Flier, J. S. (2001) · Cell · doi:10.1016/s0092-8674(01)00240-9 · Cited by 2,398
Frederich, R. C., Hamann, A., Anderson, S., Löllmann, B., Lowell, B. B., & Flier, J. S. (1995) · Nature Medicine · doi:10.1038/nm1295-1311 · Cited by 1,660
Green, H., & Kehinde, O. (1975) · Cell · doi:10.1016/0092-8674(75)90087-2 · Cited by 1,360
Dietary fat intake does affect obesity!
Bray, G. A., & Popkin, B. M. (1998) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/68.6.1157 · Cited by 1,123
Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis
Goldberg, I. J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37569-6 · Cited by 1,010
Cited by
Items 101–200 of 972
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 152
“Initial reports that GIPR null mice [64] are protected from diet-induced obesity have been supported by preclinical studies in rodents and non-human primates that GIPR antagonism induces additive weight loss when combined with GLP-1R agonism [32,67], and human genetics data that loss-of-function GIPR variants associat…”
BackgroundFujita, Y., Wideman, R. D., Asadi, A., Yang, G. K., Baker, R. K., Webber, T. D., Zhang, T., Wang, R., Ao, Z., Warnock, G. L., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.049 · Cited by 166
Killion, E. A., Chen, M., Falsey, J. R., Sivits, G., Hager, T., Atangan, L., Helmering, J., Lee, J., Li, H., Wu, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18751-8 · Cited by 151
Campbell, J. E., Müller, T. D., Finan, B., DiMarchi, R. D., Tschöp, M. H., & D’Alessio, D. A. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.010 · Cited by 149
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Tan, Q., Akindehin, S. E., Orsso, C. E., Waldner, R. C., DiMarchi, R. D., Müller, T. D., & Haqq, A. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.838410 · Cited by 146
“The observation that global loss of Gipr protects from dietinduced obesity (177) and that GIP can promote adipocyte lipid storage (163) has inspired the development of GIPR antagonists for the treatment of obesity (182).”
BackgroundInfluentialGut hormones in microbiota-gut-brain cross-talk
Sun, L.-J., Li, J.-N., & Nie, Y.-Z. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000706 · Cited by 145
“However, its role in food intake is debated as there was evidence suggesting it might rather promote adiposity.([41]) A recent study identified that the neurons expressing the GIP receptor play a key role in food intake control in mouse and human brain,([42]) which provide novel insights into the functions of GIP.”
BackgroundThe intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Bany Bakar, R., Reimann, F., & Gribble, F. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00830-y · Cited by 144
“…that GIP supports lipid storage in adipose tissue by increasing adipose tissue glucose uptake, de novo lipogenesis from glucose and re-esterification of FFAs into triglycerides 144–147 , and the observation that knockout of the GIP receptor in mice protects against diet-induced obesity 142,148 .”
BackgroundTargeting the glucagon receptor family for diabetes and obesity therapy
Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 156
Bergmann, N. C., Lund, A., Gasbjerg, L. S., Meessen, E. C. E., Andersen, M. M., Bergmann, S., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., et al. (2019) · Diabetologia · doi:10.1007/s00125-018-4810-0 · Cited by 142
Self-citationTCF1 links GIPR signaling to the control of beta cell function and survival
Campbell, J. E., Ussher, J. R., Mulvihill, E. E., Kolic, J., Baggio, L. L., Cao, X., Liu, Y., Lamont, B. J., Morii, T., Streutker, C. J., et al. (2016) · Nature Medicine · doi:10.1038/nm.3997 · Cited by 142
Iwasaki, K., Harada, N., Sasaki, K., Yamane, S., Iida, K., Suzuki, K., Hamasaki, A., Nasteska, D., Shibue, K., Joo, E., et al. (2015) · Endocrinology · doi:10.1210/en.2014-1653 · Cited by 132
“Thus, GIP has both direct and indirect effects on the accumulation of energy into adipose tissue (10).”
Obesity and the role of gut and adipose hormones in female reproduction
Gosman, G. G., Katcher, H. I., & Legro, R. S. (2006) · Human Reproduction Update · doi:10.1093/humupd/dml024 · Cited by 162
“of fat as their preferred energy source (Miyawaki et al., 2002).”
Song, D. H., Getty–Kaushik, L., Tseng, E., Simon, J., Corkey, B. E., & Wolfe, M. M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.09.005 · Cited by 137
Vaccination against GIP for the Treatment of Obesity
Fulurija, A., Lutz, T. A., Sladko, K., Osto, M., Wielinga, P. Y., Bachmann, M. F., & Saudan, P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003163 · Cited by 136
“These findings are in accordance with previous findings in GIPR mice showing little [17] or no difference [32] in age-related body weight gain in mice fed normal chow.”
BackgroundResultInfluentialGlucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification
Getty‐Kaushik, L., Song, D. H., Boylan, M. O., Corkey, B. E., & Wolfe, M. M. (2006) · Obesity · doi:10.1038/oby.2006.129 · Cited by 134
“(1,8) showed that GIP directly links overnutrition to obesity.”
BackgroundPhysiology of Incretins in Health and Disease
Deacon, C. F., & Åhrén, B. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.293 · Cited by 146
“Knock-out of the GIP receptor confers resistance to diet-induced obesity in mice [88], although there is no clear evidence at present to suggest an association between GIP and obesity in humans.”
BackgroundTargeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Campbell, J. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101139 · Cited by 133
“When fed a standard rodent diet, body weight gain was the same between wild-type (WT) and Gipr / mice [3,10]; however, the knockout mice were robustly protected from weight gain when fed a high-fat diet [10].”
BackgroundInfluentialThe emerging science of body weight regulation and its impact on obesity treatment
Körner, J., & Aronne, L. J. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17953 · Cited by 133
“Injection of PYY decreases NPY and increases POMC neuronal activity, and reduces food intake in rodents and humans (12).”
InfluentialAsmar, M., Asmar, A., Simonsen, L., Gasbjerg, L. S., Sparre-Ulrich, A. H., Rosenkilde, M. M., Hartmann, B., Dela, F., Holst, J. J., & Bülow, J. (2017) · Diabetes · doi:10.2337/db17-0480 · Cited by 132
“Previous in vitro and animal studies have shown that GIP may play a role in obesity and have suggested that GIP receptor may represent a target for the prevention and treatment of obesity (29,30).”
Self-citationEmerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases
Clemmensen, C., Finan, B., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Hofmann, S. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0118-x · Cited by 134
Gault, V. A., McClean, P. L., Cassidy, R. S., Irwin, N., & Flatt, P. R. (2007) · Diabetologia · doi:10.1007/s00125-007-0710-4 · Cited by 133
“Such a view is reinforced by studies conducted using GIP receptor knockout mice [2, 31].”
BackgroundResultInfluentialDifferential Antidiabetic Efficacy of Incretin Agonists Versus DPP-4 Inhibition in High Fat–Fed Mice
Lamont, B. J., & Drucker, D. J. (2007) · Diabetes · doi:10.2337/db07-1202 · Cited by 133
Incretin effect: GLP-1, GIP, DPP4
Kazakos, K. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70011-0 · Cited by 153
Yamagishi, S., Fukami, K., & Matsui, T. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0176-5 · Cited by 135
“However, native GLP-1 and GIP have a very short half-life because they are rapidly degraded and inactivated by proteolytic enzyme, DPP-4 [59,60], and GIP is also recognized as an obesity-promoting factor in rats fed a high-fat diet [61].”
BackgroundIncretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
Boer, G. A., & Holst, J. J. (2020) · Biology · doi:10.3390/biology9120473 · Cited by 152
Self-citationWachters-Hagedoorn, R. E., Priebe, M. G., Heimweg, J., Heiner, A. M., Englyst, K. N., Holst, J. J., Stellaard, F., & Vonk, R. J. (2006) · Journal of Nutrition · doi:10.1093/jn/136.6.1511 · Cited by 135
“GIP receptor knockout (GIPR / ) mice were shown to be resistant to obesity induced by a high-fat diet (8).”
BackgroundSelf-citationTransforming obesity: The advancement of multi-receptor drugs
Kusminski, C. M., Perez-Tilve, D., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Scherer, P. E. (2024) · Cell · doi:10.1016/j.cell.2024.06.003 · Cited by 126
Irwin, N., & Flatt, P. R. (2009) · Diabetologia · doi:10.1007/s00125-009-1422-8 · Cited by 133
“Transgenic mice with knockout of the GIP receptor have been particularly useful in elucidating mechanisms that underlie beneficial effects of compromised GIP action on diet-induced obesity [ 23 , 24].”
BackgroundInfluentialGLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“7), leaving behind an N-terminal fragment (proglucagon 1–30, also called glicentin-related pancreatic peptide, GRPP) as well as a large fragment corresponding to residues 72–158, the so-called major proglucagon fragment (MPGF) 5,8 .”
Self-citationThe potential for renoprotection with incretin-based drugs
Tanaka, T., Higashijima, Y., Wada, T., & Nangaku, M. (2014) · Kidney International · doi:10.1038/ki.2014.236 · Cited by 133
Phillips, L. K., & Prins, J. B. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06491.x · Cited by 132
Incretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121
Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
Gasbjerg, L. S., Bergmann, N. C., Stensen, S., Christensen, M. B., Rosenkilde, M. M., Holst, J. J., Nauck, M., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170183 · Cited by 121
Self-citationControl of body weight: a physiologic and transgenic perspective
Frühbeck, G., & Gómez‐Ambrosi, J. (2003) · Diabetologia · doi:10.1007/s00125-003-1053-4 · Cited by 125
Kim, S.-J., Nian, C., & McIntosh, C. H. S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704896200 · Cited by 118
DPP-4 inhibitors in the treatment of type 2 diabetes
Duez, H., Cariou, B., & Staels, B. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.11.028 · Cited by 132
“Accordingly, GIP-receptor-deficient mice have defective insulin secretion in response to oral glucose [18], but resist to the development of diet- or genetically-induced obesity and have improved insulin sensitivity [19].”
BackgroundAdipose Tissue‐Derived Plasminogen Activator Inhibitor‐1 Function and Regulation
Kaji, H. (2016) · Comprehensive physiology · doi:10.1002/cphy.c160004 · Cited by 117
Nørregaard, P. K., Deryabina, M. A., Tofteng Shelton, P., Fog, J. U., Daugaard, J. R., Eriksson, P., Larsen, L. F., & Jessen, L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13034 · Cited by 116
Incretin hormone mimetics and analogues in diabetes therapeutics
Green, B. D., & Flatt, P. R. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.09.003 · Cited by 125
Central administration of GLP-1 and GIP decreases feeding in mice
NamKoong, C., Kim, M. S., Jang, B.-T., Lee, Y. H., Cho, Y.-M., & Choi, H. J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.031 · Cited by 114
Ayala, J. E., Bracy, D. P., James, F. D., Julien, B. M., Wasserman, D. H., & Drucker, D. J. (2008) · Endocrinology · doi:10.1210/en.2008-0945 · Cited by 125
Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance
Ceperuelo-Mallafré, V., Duran, X., Pachón, G., Roche, K., Garrido-Sánchez, L., Vilarrasa, N., Tinahones, F. J., Vicente, V., Pujol, J., Vendrell, J., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3350 · Cited by 112
“E912 Ceperuelo-Mallafré et al GIP Resistance in Obesity J Clin Endocrinol Metab, May 2014, 99(5):E908–E919”
BackgroundMethodInfluentialResistance to Diet-Induced Obesity in μ-Opioid Receptor–Deficient Mice
Tabarin, A., Diz-Chaves, Y., Carmona, M. D. C., Catargi, B., Zorrilla, E. P., Roberts, A. J., Coscina, D. V., Rousset, S., Redonnet, A., Parker, G. C., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3510 · Cited by 106
Green, B., Gault, V., O'Harte, F., & Flatt, P. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043382774 · Cited by 111
“These recent observations add to a growing body of evidence, which links GIP to fat deposition, obesity and glucose intolerance [54, 98-100].”
BackgroundGodinho, R., Mega, C., Teixeira‐Lemos, E., Carvalho, E., Teixeira, F. J., Fernandes, R., & Reis, F. (2015) · Journal of Diabetes Research · doi:10.1155/2015/806979 · Cited by 122
“Although GIP was shown to increase the activity of lipoprotein lipase (LPL), which hydrolyzes lipoproteinassociated triglycerides to produce free fatty acids available for local uptake [47], themolecularmechanism bywhichGIP acts on adipocytes is largely unknown.”
BackgroundSparre‐Ulrich, A. H., Hansen, L. S., Svendsen, B., Christensen, M., Knop, F. K., Hartmann, B., Holst, J. J., & ROSENKILDE, M. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13323 · Cited by 115
“The therapeutic potential of targeting the GIP receptor In the wake of the GIP receptor KO studies demonstrating resistance to diet-induced obesity (Miyawaki et al., 2002), many have tried to antagonize the GIP receptors as a potential target for treating obesity.”
BackgroundSelf-citationLiskiewicz, A., Khalil, A., Liskiewicz, D., Novikoff, A., Grandl, G., Maity-Kumar, G., Gutgesell, R. M., Bakhti, M., Bastidas-Ponce, A., Czarnecki, O., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00931-7 · Cited by 110
Nutrient-Induced Cellular Mechanisms of Gut Hormone Secretion
Lu, V. B., Gribble, F. M., & Reimann, F. (2021) · Nutrients · doi:10.3390/nu13030883 · Cited by 117
“Animal models with diminished GIP activity including Gipr knockout mice [314], enteroendocrine K-cell ablation [315], and GIPR antagonism [316,317] show reduced body weight gain”
BackgroundPrediction of Causal Candidate Genes in Coronary Artery Disease Loci
Brænne, I., Civelek, M., Vilne, B., Di Narzo, A., Johnson, A. D., Zhao, Y., Reiz, B., Codoni, V., Webb, T. R., Foroughi Asl, H., et al. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306108 · Cited by 109
“Mouse knockout models of Gip showed reduced obesity and insulin resistance.(40,41) In our mouse data set,(37) we also found positive correlation”
BackgroundGut hormone polyagonists for the treatment of type 2 diabetes
Brandt, S. J., Götz, A., Tschöp, M. H., & Müller, T. D. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.021 · Cited by 110
Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1
Riddle, M. C., & Drucker, D. J. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1267 · Cited by 109
“In an intriguing finding, GIP receptor / mice exhibit decreased adipose tissue mass, improved insulin sensitivity, and resistance to diet-induced obesity (99).”
BackgroundMusso, G., Gambino, R., Pacini, G., De Michieli, F., & Cassader, M. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26720 · Cited by 107
Metabolic surgery and gut hormones – A review of bariatric entero-humoral modulation
Ashrafian, H., & le Roux, C. W. (2009) · Physiology & Behavior · doi:10.1016/j.physbeh.2009.03.012 · Cited by 112
Targeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins
Salehi, M., Aulinger, B. A., & D’Alessio, D. A. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0031 · Cited by 118
Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition
Kaneko, K., Fu, Y., Lin, H.-Y., Cordonier, E. L., Mo, Q., Gao, Y., Yao, T., Naylor, J., Howard, V., Saito, K., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126107 · Cited by 106
“Since endogenous GIP is produced in K cells in the upper gut and GIP levels are reported to be elevated in diet-induced obesity, reaching 20–100 pM (9, 14, 24, 25), we next determined whether increasing the peripheral levels of GIP inhibits neural leptin actions.”
BackgroundInfluentialMechanisms responsible for excess weight loss after bariatric surgery
Ionut, V., & Bergman, R. N. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500536 · Cited by 105
Therapeutic potential for GIP receptor agonists and antagonists
Irwin, N., & Flatt, P. R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.001 · Cited by 114
Suzuki, K., Harada, N., Yamane, S., Nakamura, Y., Sasaki, K., Nasteska, D., Joo, E., Shibue, K., Harada, T., Hamasaki, A., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.423137 · Cited by 101
“GIP binds to theGIP receptor (GIPR) on the surface of pancreatic -cells, adipose tissue, and osteoblasts, and it stimulates insulin secretion (6), fat accumulation (7), and bone formation (8), respectively, by increasing the level of intracellular adenosine 3 ,5 -monophosphate (cAMP).”
BackgroundMohammad, S., Patel, R. T., Bruno, J., Panhwar, M. S., Wen, J., & McGraw, T. E. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00256-14 · Cited by 104
“GIP (1-30) a peptide of amino acids 1 to 30 of”
Widenmaier, S. B., Kim, S. J., Yang, G. K., Reyes, T. D. L., Nian, C., Asadi, A., Seino, Y., Kieffer, T. J., Kwok, Y. N., & McIntosh, C. H. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009590 · Cited by 110
“The main reasons for this are that many patients with diabetes exhibit greatly reduced insulin responses to GIP and that elimination of GIP signaling promotes resistance to obesity in rodents [19,20,21,22], suggesting that GIPR agonists would be ineffective in restoring bcell function and may increase obesity in patie…”
BackgroundSelf-citationGut hormone co-agonists for the treatment of obesity: from bench to bedside
Nogueiras, R., Nauck, M. A., & Tschöp, M. H. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00812-z · Cited by 102
Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?
Gault, V. A., O'Harte, F. P. M., & Flatt, P. R. (2003) · Neuropeptides · doi:10.1016/j.npep.2003.09.002 · Cited by 107
Irwin, N., McClean, P. L., O'Harte, F. P. M., Gault, V. A., Harriott, P., & Flatt, P. R. (2007) · Diabetologia · doi:10.1007/s00125-007-0692-2 · Cited by 106
“Experimental evidence in mice also indicates that inhibition of GIP signalling by genetic knockout of the GIP receptor prevents diet-induced obesity through the preferential use of fat as an energy substrate [30].”
BackgroundResultInfluentialSuccessful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36
Iepsen, E. W., Lundgren, J., Holst, J. J., Madsbad, S., & Torekov, S. S. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1116 · Cited by 101
Self-citationObesity: Its Epidemiology, Comorbidities, and Management
Jarolimova, J., Tagoni, J. R., & Stern, T. A. (2013) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.12f01475 · Cited by 116
Glucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 112
Self-citationJoo, E., Harada, N., Yamane, S., Fukushima, T., Taura, D., Iwasaki, K., Sankoda, A., Shibue, K., Harada, T., Suzuki, K., et al. (2017) · Diabetes · doi:10.2337/db16-0758 · Cited by 104
“We previously showed that fat accumulation in adipose tissue is inhibited in GIPR mice compared with WT mice under the HFD-fed condition (17).”
BackgroundNovikoff, A., O'Brien, S. L., Bernecker, M., Grandl, G., Kleinert, M., Knerr, P. J., Stemmer, K., Klingenspor, M., Zeigerer, A., DiMarchi, R., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101181 · Cited by 95
“Mice with GIP receptor (GIPR) depletion are protected from dietinduced obesity [12], and patients with type 2 diabetes show an impaired insulinotropic response to GIP infusion [13].”
BackgroundRuiz‐Gómez, G., Tyndall, J. D. A., Pfeiffer, B., Abbenante, G., & Fairlie, D. P. (2010) · Chemical Reviews · doi:10.1021/cr900344w · Cited by 102
Hansen, L. S., Sparre‐Ulrich, A. H., Christensen, M., Knop, F. K., Hartmann, B., Holst, J. J., & ROSENKILDE, M. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13384 · Cited by 97
“BJP British Journal ofPharmacology DOI:10.1111/bph.13384 www.brjpharmacol.org”
InfluentialSelf-citationK-cells and Glucose-Dependent Insulinotropic Polypeptide in Health and Disease
Cho, Y. M., & Kieffer, T. J. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00004-7 · Cited by 110
Sánchez‐Tapia, M., Aguilar‐López, M., Perez‐Cruz, C., Pichardo‐Ontiveros, E., Wang, M., Donovan, S. M., Tovar, A. R., & Torres, N. (2017) · Scientific Reports · doi:10.1038/s41598-017-05096-4 · Cited by 101
Link between GIP and osteopontin in adipose tissue and insulin resistance
Ahlqvist, E., Osmark, P., Kuulasmaa, T., Pilgaard, K., Omar, B., Brøns, C., Kotova, O., Zetterqvist, A. V., Stančáková, A., Jonsson, A., et al. (2013) · Diabetes · doi:10.2337/db12-0976 · Cited by 96
“GIP stimulates adipose tissue formation independently of its effect on insulin secretion (5), and inactivation of the GIP receptor (GIPR) in adipose tissue has been suggested as a strategy to treat obesity (6).”
BackgroundThe Effects of Bariatric Surgery on Pancreatic Lipid Metabolism and Blood Flow
Honka, H., Koffert, J., Hannukainen, J. C., Tuulari, J. J., Karlsson, H. K., Immonen, H., Oikonen, V., Tolvanen, T., Soinio, M., Salminen, P. T. P., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4236 · Cited by 97
Pleiotropic Effects of GIP on Islet Function Involve Osteopontin
Lyssenko, V., Eliasson, L., Kotova, O., Pilgaard, K., Wierup, N., Salehi, A., Wendt, A., Jonsson, A., De Marinis, Y. Z., Berglund, L. M., et al. (2011) · Diabetes · doi:10.2337/db10-1532 · Cited by 98
Gögebakan, Ö., Osterhoff, M. A., Schüler, R., Pivovarova, O., Kruse, M., Seltmann, A.-C., Mosig, A. S., Rudovich, N., Nauck, M., & Pfeiffer, A. F. H. (2015) · Diabetologia · doi:10.1007/s00125-015-3618-4 · Cited by 95
“In Ob/Ob mice, deletion of Gipr or treatment with GIP antagonists leads to major improvements of metabolism and insulin sensitivity despite persisting obesity [16, 17, 35].”
BackgroundAyala, J. E., Bracy, D. P., James, F. D., Burmeister, M. A., Wasserman, D. H., & Drucker, D. J. (2010) · Endocrinology · doi:10.1210/en.2010-0289 · Cited by 95
Gault, V. A., Flatt, P. R., & O'Harte, F. P. M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01361-5 · Cited by 99
Replication of 13 obesity loci among Singaporean Chinese, Malay and Asian-Indian populations
Dorajoo, R., Blakemore, A. I. F., Sim, X., Ong, R. T., Ng, D. P. K., Seielstad, M. T., Wong, T., Saw, S., Froguel, P., Liu, J., et al. (2011) · International Journal of Obesity · doi:10.1038/ijo.2011.86 · Cited by 104
Diet: Friend or Foe of Enteroendocrine Cells: How It Interacts with Enteroendocrine Cells
Morán‐Ramos, S., Tovar, A. R., & Torres, N. (2012) · Advances in Nutrition · doi:10.3945/an.111.000976 · Cited by 111
“These and other data suggest that GIP as is a metabolically thrifty gene and postulate it as possible link between overnutrition and obesity (31,33,34).”
BackgroundKillion, E. A., Lu, S.-C., Fort, M., Yamada, Y., Véniant, M. M., & Lloyd, D. J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz002 · Cited by 94
Self-citationGabe, M. B. N., Sparre‐Ulrich, A. H., Pedersen, M. F., Gasbjerg, L. S., Inoue, A., Bräuner‐Osborne, H., Hartmann, B., & ROSENKILDE, M. M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.040 · Cited by 96
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Rao, R. S., & Kini, S. U. (2010) · Obesity Surgery · doi:10.1007/s11695-010-0305-x · Cited by 101
“GIP promotes obesity and increased peripheral insulin resistance as has been shown in animals [ 21 ].”
BackgroundTschöp, M., Nogueiras, R., & Ahrén, B. (2023) · Diabetologia · doi:10.1007/s00125-023-05929-0 · Cited by 92
“Consistent with this, whole-body GIP receptor deficiency and GIP deficiency protect against obesity induced by long-term high fat feeding in mice [65, 66].”
BackgroundLu, S.-C., Chen, M., Atangan, L., Killion, E. A., Komorowski, R., Cheng, Y., Netirojjanakul, C., Falsey, J. R., Stolina, M., Dwyer, D., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100263 · Cited by 91
Gut–Brain Axis: Regulation of Glucose Metabolism
Heijboer, A. C., Pijl, H., van den Hoek, A. M., Havekes, L. M., Romijn, J. A., & Corssmit, E. P. M. (2006) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2006.01492.x · Cited by 101
Hodge, D., Marsh, W. J., Parker, H. E., Ogunnowo-Bada, E., Riches, C. H., Habib, A. M., Evans, M. L., Gribble, F. M., & Reimann, F. (2012) · Diabetologia · doi:10.1007/s00125-012-2663-5 · Cited by 91
“Although it acts as an incretin hormone to promote insulin secretion, mice lacking GIP receptors show only a mild impairment of postprandial glucose homeostasis [2], but appear to be protected from the obesogenic effects of either a high-fat diet or the hyperphagic leptin deficient ob/ob background [3].”
BackgroundTimper, K., Grisouard, J., Sauter, N. S., Herzog-Radimerski, T., Dembinski, K., Peterli, R., Frey, D. M., Zulewski, H., Keller, U., Müller, B., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00100.2012 · Cited by 88
“Ablation of GIP receptor activation protects against dietinduced obesity and insulin resistance (19, 42), pointing to an important role of GIP in adipose tissue.”
BackgroundMaida, A., Hansotia, T., Longuet, C., Seino, Y., & Drucker, D. J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.09.004 · Cited by 88
Self-citationPharmacological Characterization of Human Incretin Receptor Missense Variants
Fortin, J., Schroeder, J. C., Zhu, Y., Beinborn, M., & Kopin, A. S. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.160531 · Cited by 99
“Loss of function in the GIP-R could provide a potential mechanism for altered glucose homeostasis or fat deposition (Miyawaki et al., 2002; Gault et al., 2007; Fulurija et al., 2008; Kim and Egan, 2008).”
Qi, Q., Bray, G. A., Hu, F. B., Sacks, F. M., & Qi, L. (2012) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.025270 · Cited by 93
Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism
Trzaskalski, N. A., Fadzeyeva, E., & Mulvihill, E. E. (2020) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551420912972 · Cited by 96
Peripheral tissue–brain interactions in the regulation of food intake
López, M., Tovar, S. A., Vazquez, M. J., Williams, L. M., & Diéguez, C. (2007) · Proceedings of The Nutrition Society · doi:10.1017/s0029665107005368 · Cited by 98
“2004; Badman & Flier, 2005), whereas mice lacking the gastric inhibitory polypeptide receptor are protected against obesity induced by both a high-fat diet and leptin deficiency (ob/ob mice; Miyawaki et al. 2002).”
BackgroundGlucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents
Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.021 · Cited by 85
Self-citationYamaoka‐Tojo, M., Tojo, T., Takahira, N., Matsunaga, A., Aoyama, N., Masuda, T., & Izumi, T. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-17 · Cited by 87
“According to a previous study using mice with an inactivated GIP receptor, the duodenal hormone GIP directly links over-nutrition to obesity [22].”
Ravn, P., Madhurantakam, C., Kunze, S., Matthews, E., Priest, C., O’Brien, S., Collinson, A., Papworth, M. A., Fredin, M. F., Jermutus, L., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.426288 · Cited by 87
“Conversely, reduced body weight gain has been observed in diet-induced obesity models in a GIPr / knock-out mouse (49), upon immunization with GIP to generate antagonistic antibodies, and upon administration of theGIPr peptide antagonist Pro3GIP or ablation of GIPproducing K cells (50–53).”
BackgroundPharmacological Approaches to Weight Reduction: Therapeutic Targets
Körner, J., & Aronne, L. J. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0341 · Cited by 90
Leveraging the Gut to Treat Metabolic Disease
Gimeno, R. E., Briere, D. A., & Seeley, R. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.014 · Cited by 83
On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans
Asmar, M., Tangaa, W., Madsbad, S., Hare, K. J., Astrup, A. V., Flint, A., Bülow, J., & Holst, J. J. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00639.2009 · Cited by 91
“Synthetic human GIP-(1-42) (PolyPeptide Laboratories, Wolfenbüttel, Germany) was dissolved in sterilized water containing 2% human serum albumin (CSL Behring, Marburg, Germany; viral safety was achieved by the procedures specified in The European Pharmacopoeia) and subjected to sterile filtration.”
BackgroundMethodSelf-citation
Metadata
- Authors
- Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., Hiai, H., Mizunoya, W., Fushiki, T., Holst, J. J., Makino, M., Tashita, A., Kobara, Y., Tsubamoto, Y., Jinnouchi, T., Jomori, T., & Seino, Y.
- Affiliations
- Kyoto University (JP)
- University of Copenhagen (DK)
- Sanwa Kagaku Kenkyusho Co., Ltd. (Japan) (JP)
- Corresponding author
- Seino, Yutaka
- Venue
- Nature Medicine
- Published
- 2002-06-17
- Volume
- 8
- Issue
- 7
- Pages
- 738-742
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2102392334
- Cited by
- 963
- References
- 24
- Citations by year
- 2026: 34 · 2025: 43 · 2024: 64 · 2023: 45 · 2022: 38 · 2021: 39 · 2020: 37 · 2019: 66 · 2018: 39 · 2017: 45 · 2016: 38 · 2015: 42 · 2014: 44 · 2013: 38 · 2012: 38
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP receptor, obesity, insulin resistance, high-fat diet, adiposity, respiratory quotient, fat oxidation, anti-obesity drugs, overnutrition
- MeSH terms
- Adipose Tissue, Animals, Body Weight, Crosses, Genetic, Dietary Fats, Gastric Inhibitory Polypeptide, Obesity, Receptors, Gastrointestinal Hormone, Signal Transduction, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.